PureTech Health plc (LON:PRTC)
124.20
+0.20 (0.16%)
Nov 4, 2026, 4:35 PM GMT
PureTech Health Employees
PureTech Health had 90 employees as of December 31, 2025. The number of employees increased by 34 or 60.71% compared to the previous year. That makes PureTech Health the 32,068th largest employer in the world and 648th in the United Kingdom.
Employees
90
Change (1Y)
34
Growth (1Y)
60.71%
Revenue / Employee
53.30K GBP
Profits / Employee
17.70K GBP
Market Cap
304.51M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 90 | 34 | 60.71% |
| Dec 31, 2024 | 56 | -34 | -37.78% |
| Dec 31, 2023 | 90 | -21 | -18.92% |
| Dec 31, 2022 | 111 | 16 | 16.84% |
| Dec 31, 2021 | 95 | -155 | -62.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Genus | 2,921 |
| Oxford Nanopore Technologies | 1,314 |
| Oxford Biomedica | 1,017 |
| 4basebio | 140 |
| Avacta Group | 81 |
| Scancell Holdings | 55 |
| Faron Pharmaceuticals Oy | 36 |
| Hemogenyx Pharmaceuticals | 16 |
PureTech Health News
- 5 days ago - PureTech Health Wins 2026 Prix Galien USA Award in Incubators, Accelerators and Equity Category - Business Wire
- 9 days ago - PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026 - Business Wire
- 16 days ago - PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026 - Business Wire
- 26 days ago - PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress - Business Wire
- 6 weeks ago - PureTech Health Earnings Call Transcript: H1 2026 - Transcripts
- 6 weeks ago - PureTech Health Quarterly report: H1 2026 - Filings
- 6 weeks ago - PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) - Business Wire
- 2 months ago - PureTech Health: Notice of Half-Yearly Results - Business Wire